hereditary haemochromatosis

in review 4 min read Updated 2026-10-28
hereditary haemochromatosis

Autosomal recessive iron-overload disorder, overwhelmingly due to C282Y homozygosity in the HFE gene. Screen with transferrin saturation (Tsat; fasting not required) and ferritin — HFE genotyping when Tsat ≥45% with raised ferritin (EASL uses Tsat >50% in men) (or a first-degree relative with HFE disease). Treat C282Y homozygotes once ferritin is raised (>300 µg/L men/post-menopausal women, >200 µg/L pre-menopausal women). Clinical penetrance is incomplete (~28% of male and ~1% of female C282Y homozygotes develop clinical disease). Phlebotomy is curative when started before cirrhosis. Liver biopsy is no longer routine — reserve for staging when ferritin >1000 µg/L or ALT is elevated. HCC surveillance is lifelong once cirrhosis is established, even after iron depletion.


diagnostic algorithm

flowchart TD
    A["elevated ferritin or<br>clinical suspicion"] --> B["Tsat"]
    B -->|"< 45%"| C["haemochromatosis<br>excluded"]
    B -->|"≥ 45%"| D["HFE genotyping"]
    D -->|"C282Y/C282Y"| E["hereditary<br>haemochromatosis confirmed"]
    D -->|"C282Y/H63D"| F["low risk of iron<br>overload — investigate<br>other causes"]
    D -->|"H63D/H63D or<br>wild type"| G["not HFE-related —<br>consider secondary<br>causes or rare types"]
    E --> H{"ferritin"}
    H -->|"< 1000 µg/L<br>+ normal ALT"| I["phlebotomy<br>no biopsy needed"]
    H -->|"≥ 1000 µg/L<br>or elevated ALT"| J["liver biopsy or<br>LSM → assess<br>for cirrhosis"]
ferritin is not a screening test for haemochromatosis

Ferritin is an acute-phase reactant elevated by inflammation, infection, MASLD, alcohol, and malignancy. Transferrin saturation is the screening test. Tsat <45% has ~97% NPV for excluding iron overload (see approach to elevated liver enzymes).


HFE genotypes and penetrance

genotypeiron-overload risknotes
C282Y/C282Yhighest — ~28% M, ~1% F develop clinical diseasethe classic haemochromatosis genotype
C282Y/H63Dlow (~1–2% develop mild overload)most compound heterozygotes never develop significant disease; look for a cofactor (alcohol, MASLD) if ferritin is high
H63D/H63Dnegligibledoes not cause clinically significant iron overload on its own

Penetrance is modified by sex (premenopausal women protected by menstrual losses), alcohol, hepatic steatosis, and other genetic modifiers.


organ involvement

Iron accumulates preferentially in parenchymal cells. Clinical manifestations typically appear after age 40 in men, post-menopause in women.

organmanifestation
liverelevated ALT → fibrosis → cirrhosis → HCC (risk persists after iron depletion if cirrhosis established)
pancreas“bronze diabetes” — T2DM from beta-cell iron deposition; may not reverse with phlebotomy
heartdilated or restrictive cardiomyopathy, arrhythmias (particularly in juvenile haemochromatosis)
joints2nd/3rd MCP arthropathy (chondrocalcinosis), may worsen despite iron depletion
pituitaryhypogonadotropic hypogonadism — check testosterone/LH/FSH
skinbronze hyperpigmentation
arthropathy does not improve with phlebotomy

Joint symptoms are the most treatment-resistant manifestation and may even progress after iron normalisation. Early treatment prevents other organ damage but does not reliably prevent or reverse arthropathy.


treatment

phlebotomy

The mainstay — effective, safe, and curative if started before irreversible organ damage.

Induction phase:

  • 500 mL whole blood (≈250 mg iron) every 1–2 weeks
  • target: ferritin <50 µg/L during induction (EASL; ACG 50–100)
  • monitor ferritin every 4–6 phlebotomy sessions; check Hb before each session (hold if Hb <110 g/L)

Maintenance phase:

  • phlebotomy every 1–4 months (typically 3–4×/year) to keep ferritin 50–100 µg/L
  • lifelong

when phlebotomy is not possible

  • Chelation therapy (deferasirox) — reserved for patients with anaemia, poor venous access, or intolerance to phlebotomy. More side effects and cost than phlebotomy.
  • Erythrocytapheresis — removes more iron per session; consider if poor tolerance to volume removal

dietary advice

  • avoid iron supplements and vitamin C supplements (enhances iron absorption)
  • avoid excess alcohol (synergistic hepatotoxicity)
  • raw shellfish avoidance — Vibrio vulnificus sepsis risk with iron overload (rare but classically tested)
  • no need for a low-iron diet; the above restrictions suffice

HCC surveillance

  • All patients with cirrhosis — lifelong, even if fibrosis regresses after treatment → hepatocellular carcinoma
  • HCC risk persists after iron depletion if cirrhosis was present at diagnosis
  • Without cirrhosis: ACG suggests against HCC surveillance (≤F3); EASL suggests it with advanced fibrosis (F3) and after regression from cirrhosis. Assess fibrosis non-invasively at diagnosis.

family screening

  • First-degree relatives of a confirmed C282Y homozygote should be offered HFE genotyping + Tsat + ferritin
  • If partner is tested and is not a C282Y carrier → children are obligate heterozygotes and do not need further testing
  • Screening is most impactful in siblings (25% chance of homozygosity)

key points

  • Ferritin alone never justifies HFE testing (Choosing Wisely Canada) — most raised ferritins are inflammation, alcohol or MASLD.
  • H63D homozygosity doesn’t cause clinically significant iron overload; C282Y/H63D with raised ferritin usually has a second driver (alcohol, obesity) — treat that; phlebotomy if iron overload is confirmed (ACG treats it as HH).
  • Young C282Y homozygotes can have normal ferritin with raised Tsat — Tsat rises first.
  • Cirrhosis → HCC surveillance continues after iron depletion (hepatocellular carcinoma).

related: approach to elevated liver enzymes · cirrhosis · MASLD · autoimmune hepatitis · primary biliary and sclerosing cholangitis · Wilson disease

Prepared 2026-10-28. Not yet verified — check every number against the sources.

Key references

+2 more sources

Suggest a correction hereditary haemochromatosis